Clinical Trials Directory

Trials / Completed

CompletedNCT03543085

Ultra-high Frequency (500 KHz) Spinal Cord Stimulation for Treatment of Chronic Back Pain or Lower Limb Pain

A Single-arm, Open Label, Single Center, Prospective Study of Ultra-high Frequency (500 KHz) Spinal Cord Stimulation for Treatment of Chronic Back Pain or Lower Limb Pain

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
GiMer Medical · Industry
Sex
All
Age
20 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain.

Detailed description

This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain. The trial length is 14 days. Patients will be given ultrahigh frequency pulse stimulation, up to 3 times in every 24 hours, and VAS will be obtained at least once a day. Compared to previous study conducted last year, patient can now have two lead implant sites for different pain locations. The electrode implantation site will be epidural space instead of Dorsal Root Ganglion (DRG).

Conditions

Interventions

TypeNameDescription
DEVICEGiMer Medical MN 1000 External StimulatorTrial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.

Timeline

Start date
2018-04-12
Primary completion
2018-10-23
Completion
2018-10-23
First posted
2018-06-01
Last updated
2021-10-13
Results posted
2021-10-13

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03543085. Inclusion in this directory is not an endorsement.